|MDACC Study No:||2010-0398 (clinicaltrials.gov NCT No: NCT01023308)|
|Title:||A Multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma|
|Principal Investigator:||Donna M. Weber|
|Treatment Agent:||Bortezomib; Dexamethasone; Panobinostat|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
panobinostat, bortezomib, and dexamethasone is safe and results in a better
anti-myeloma activity than bortezomib and dexamethasone alone.